A direct comparison of two compounds in the same section of the catalog whose evidence bases are not remotely comparable.
In short
- Amylin is co-secreted with insulin from pancreatic beta cells and acts at calcitonin-receptor-based receptor complexes in the hindbrain.
- Cagrilintide is a long-acting acylated amylin analogue; Lau and colleagues published a randomised dose-finding phase 2 trial in the Lancet in 2021.
- AOD-9604 is a fragment of the C-terminal region of human growth hormone, studied by Heffernan and colleagues in obese and beta-3-adrenergic-receptor knockout mice.
- AOD-9604 went into human clinical development and did not demonstrate the efficacy required to proceed. That outcome is part of its evidence base and belongs in any honest summary.
The amylin system
Amylin, or islet amyloid polypeptide, is a 37-residue peptide released alongside insulin from pancreatic beta cells. Its receptors are composite: the calcitonin receptor in complex with receptor activity-modifying proteins, expressed prominently in hindbrain regions including the area postrema, which is one of the circumventricular organs with access to circulating signals.
The physiological role described in the literature is in meal-related satiation signalling and gastric emptying — a pathway distinct from the incretin system, which is why the two have been combined in development programmes. Pramlintide, an earlier amylin analogue, established that the pathway was pharmacologically addressable in humans.
What the cagrilintide trial reported
Cagrilintide is an acylated amylin analogue engineered for once-weekly administration. Lau and colleagues published a randomised, double-blind, dose-finding phase 2 trial in the Lancet in 2021, with body weight as the primary endpoint, across multiple dose levels against placebo and an active comparator. The trial reported dose-dependent weight reduction over the treatment period, with gastrointestinal adverse events the most common tolerability finding.
Later work reported co-administration with semaglutide in phase 2 in type 2 diabetes, also in the Lancet, in 2023. The development programme is ongoing and the compound is not approved.
The relevant point for this catalog is the level of evidence: a registered, randomised, published human trial with a pre-specified endpoint. That is a substantially different object from a rodent study, and the difference should be visible when reading across a catalog section rather than flattened by the fact that both compounds appear on the same page.
The growth-hormone fragment, and a negative result that matters
AOD-9604 corresponds to the C-terminal region of human growth hormone, the segment associated in earlier work with the hormone's lipolytic rather than its growth-promoting activity. The design intent was separation: retain the effect on fat metabolism, drop the IGF-1-mediated growth signalling.
Heffernan and colleagues reported the core preclinical work in Endocrinology in 2001, comparing human growth hormone and the fragment in obese mice and in beta-3-adrenergic-receptor knockout mice, and measuring lipid-metabolism endpoints and body composition after chronic treatment. The knockout arm was included to test whether the effect required that receptor.
What followed is the part usually omitted. The compound entered human clinical development for obesity and the programme did not produce the efficacy needed to continue. A negative clinical result is evidence, and a summary that cites the mouse data while passing over the human outcome has inverted the weight of the record. The compound is not approved, and the WADA prohibited list covers growth-hormone fragments.
Reading a catalog section honestly
The Metabolic world holds three compounds whose evidence runs from a published randomised human trial to rodent-only work to a mitochondrial signalling story. Grouping them reflects a shared research question — energy, appetite and metabolic signalling — and nothing more.
No page in that world describes weight, appetite or metabolism in a person, none carries dosing, and none of the compounds is supplied for any use in people.
References
- Lau DCW, Erichsen L, Francisco AM, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160–2172.
- Heffernan MA, Thorburn AW, Fam B, et al.. Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189.
What this article is, and is not
This is a summary of published research, written for qualified professionals evaluating compounds for laboratory work. Every compound discussed is supplied by strictly for in-vitro and laboratory research use. None is a drug, a dietary supplement, or a cosmetic; none is intended for human or veterinary use; and nothing above is medical advice, a treatment recommendation, or a claim that any compound produces any effect in a person. We publish no dosing or administration guidance of any kind.
